| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FETUB |
| Uniprot No | Q9UGM5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 16-382aa |
| 氨基酸序列 | CGAMSPPQLALNPSALLSRGCNDSDVLAVAGFALRDINKDRKDGYVLRLN RVNDAQEYRRGGLGSLFYLTLDVLETDCHVLRKKAWQDCGMRIFFESVYG QCKAIFYMNNPSRVLYLAAYNCTLRPVSKKKIYMTCPDCPSSIPTDSSNH QVLEAATESLAKYNNENTSKQYSLFKVTRASSQWVVGPSYFVEYLIKESP CTKSQASSCSLQSSDSVPVGLCKGSLTRTHWEKFVSVTCDFFESQAPATG SENSAVNQKPTNLPKVEESQQKNTPPTDSPSKAGPRGSVQYLPDLDDKNS QEKGPQEAFPVHLDLTTNPQGETLDISFLFLEPMEEKLVVLPFPKEKART AECPGPAQNASPLVLPP |
| 预测分子量 | 42 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FETUB重组蛋白的3篇参考文献示例(注：文献为虚拟示例，实际引用时请核实真实来源)：
---
1. **文献名称**: "Expression and Functional Characterization of Recombinant Human Fetuin-B in HEK293 Cells"
**作者**: Tanaka M, et al.
**摘要**: 研究报道了在HEK293细胞中高效表达重组人FETUB蛋白的方法，并验证其通过抑制半胱氨酸蛋白酶参与卵母细胞成熟的分子机制。
---
2. **文献名称**: "Recombinant Murine Fetuin-B Ameliorates Insulin Resistance in Obese Mouse Models"
**作者**: Kumar S, et al.
**摘要**: 通过大肠杆菌系统表达重组鼠源FETUB蛋白，实验表明其通过调节脂代谢通路改善肥胖小鼠的胰岛素敏感性，提示其在代谢疾病治疗中的潜力。
---
3. **文献名称**: "Structural Analysis and Oocyte Maturation-Promoting Activity of Purified Recombinant Fetuin-B"
**作者**: Lee J, et al.
**摘要**: 采用哺乳动物表达系统纯化重组FETUB，结合体外实验证实其通过结合卵母细胞表面受体，显著提升哺乳动物卵母细胞的成熟率和受精能力。
---
**备注**：实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献，并核对作者、标题及摘要的准确性。
**Background of FETUB Recombinant Protein**
Fetuin-B (FETUB) is a liver-derived glycoprotein belonging to the cystatin superfamily, encoded by the *FETUB* gene in humans. It shares structural homology with fetuin-A, another member of the fetuin family, but exhibits distinct functional roles. FETUB is primarily recognized for its critical involvement in reproductive biology, particularly in regulating fertilization. It acts as a protease inhibitor, specifically targeting ovastacin, a metalloprotease released by the egg during the zona pellucida hardening process post-fermentation. By inhibiting ovastacin, FETUB ensures timely zona pellucida hardening, preventing polyspermy and ensuring successful embryo development.
Beyond reproduction, FETUB has been implicated in metabolic processes, including insulin signaling and lipid metabolism, though its mechanisms remain less characterized compared to fetuin-A. Dysregulation of FETUB expression has been associated with conditions such as polycystic ovary syndrome (PCOS) and metabolic syndrome, highlighting its potential as a biomarker or therapeutic target.
Recombinant FETUB protein is engineered using expression systems (e.g., mammalian or bacterial cells) to produce purified, biologically active forms for research and clinical applications. Its production enables detailed studies on structure-function relationships, interaction networks, and therapeutic potential. In vitro and in vivo models utilizing recombinant FETUB have advanced understanding of fertilization biology and metabolic diseases. However, challenges persist in optimizing its stability, post-translational modifications, and scalability for translational use. Ongoing research aims to elucidate its broader physiological roles and harness its inhibitory properties for contraceptive development or treatments for infertility and metabolic disorders.
×
